ARCTURUS THERAPEUTICS HOLDINGS INC. Increase (Decrease) in Contract with Customer, Liability
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Increase (Decrease) in Contract with Customer, Liability of -$1.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$1.33M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$636.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$2.80M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$8.99M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$23.87M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in contract with customer, liability for fiscal 2024 was -$55.21M, a 243.00% decline from fiscal 2023.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in contract with customer, liability for fiscal 2023 was $38.61M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$14.69M, a 144.81% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.97M 10-Q · filed 2026-08-06 | -$4.77M derived: sum of 3 quarters · filed 2026-08-06 | -$13.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$636.00K 10-Q · filed 2026-05-07 | -$3.44M derived: sum of 2 quarters · filed 2026-05-07 | -$12.42M derived: sum of 3 quarters · filed 2026-05-07 | -$14.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$11.79M derived: sum of 2 quarters · filed 2026-03-03 | -$14.05M derived: sum of 3 quarters · filed 2026-08-06 | -$23.87M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$8.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$11.26M derived: sum of 2 quarters · filed 2026-08-06 | -$21.07M 10-Q · filed 2025-11-12 | -$29.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$12.09M 10-Q · filed 2026-08-06 | -$20.24M derived: sum of 3 quarters · filed 2026-08-06 | -$33.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$9.82M 10-Q · filed 2026-05-07 | -$17.97M derived: sum of 2 quarters · filed 2026-05-07 | -$31.41M derived: sum of 3 quarters · filed 2026-05-07 | -$61.01M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$8.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$21.59M derived: sum of 2 quarters · filed 2026-03-03 | -$51.19M derived: sum of 3 quarters · filed 2026-03-03 | -$55.21M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$13.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$43.04M derived: sum of 2 quarters · filed 2025-11-12 | -$47.05M 10-Q · filed 2025-11-12 | -$42.41M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | -$29.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$33.62M 10-Q · filed 2025-08-11 | -$28.97M derived: sum of 3 quarters · filed 2026-03-03 | -$19.98M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$4.01M 10-Q · filed 2025-05-12 | $632.00K derived: sum of 2 quarters · filed 2026-03-03 | $9.62M derived: sum of 3 quarters · filed 2026-03-03 | $24.25M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $13.64M derived: sum of 2 quarters · filed 2026-03-03 | $28.26M derived: sum of 3 quarters · filed 2026-03-03 | $38.61M 10-K · filed 2026-03-03 |
| 2023-09-30 | $8.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $23.62M derived: sum of 2 quarters · filed 2024-11-07 | $33.96M 10-Q · filed 2024-11-07 | $72.84M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $14.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $24.97M 10-Q · filed 2024-08-05 | $63.85M derived: sum of 3 quarters · filed 2025-03-06 | $41.75M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $10.34M 10-Q · filed 2024-05-08 | $49.23M derived: sum of 2 quarters · filed 2025-03-06 | $27.12M derived: sum of 3 quarters · filed 2025-03-06 | -$641.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $38.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $16.78M derived: sum of 2 quarters · filed 2025-03-06 | -$10.98M derived: sum of 3 quarters · filed 2025-03-06 | -$14.69M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$22.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$49.87M derived: sum of 2 quarters · filed 2023-11-14 | -$53.58M 10-Q · filed 2023-11-14 | -$56.28M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | -$27.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$31.47M 10-Q · filed 2023-08-07 | -$34.17M derived: sum of 3 quarters · filed 2024-03-14 | $4.02M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | -$3.71M 10-Q · filed 2023-05-09 | -$6.41M derived: sum of 2 quarters · filed 2024-03-14 | $31.78M derived: sum of 3 quarters · filed 2024-03-14 | $30.45M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | -$2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $35.49M derived: sum of 2 quarters · filed 2024-03-14 | $34.16M derived: sum of 3 quarters · filed 2024-03-14 | $32.79M 10-K · filed 2024-03-14 |
| 2021-09-30 | $38.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $36.86M derived: sum of 2 quarters · filed 2022-11-09 | $35.49M 10-Q · filed 2022-11-09 | $46.77M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$2.70M 10-Q · filed 2022-08-09 | $8.58M derived: sum of 3 quarters · filed 2022-08-09 | $7.14M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$1.37M 10-Q · filed 2022-05-09 | $9.91M derived: sum of 2 quarters · filed 2022-05-09 | $8.47M derived: sum of 3 quarters · filed 2022-05-09 | $7.34M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $11.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $9.84M derived: sum of 2 quarters · filed 2022-03-01 | $8.71M derived: sum of 3 quarters · filed 2022-03-01 | $7.04M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$2.57M derived: sum of 2 quarters · filed 2021-11-09 | -$4.24M 10-Q · filed 2021-11-09 | -$6.21M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$2.80M 10-Q · filed 2021-08-10 | -$4.77M derived: sum of 3 quarters · filed 2022-03-01 | -$6.60M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$1.67M 10-Q · filed 2021-05-10 | -$3.64M derived: sum of 2 quarters · filed 2022-03-01 | -$5.47M derived: sum of 3 quarters · filed 2022-03-01 | $6.16M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$3.80M derived: sum of 2 quarters · filed 2022-03-01 | $7.83M derived: sum of 3 quarters · filed 2022-03-01 | $8.97M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $9.80M derived: sum of 2 quarters · filed 2020-11-09 | $10.94M 10-Q · filed 2020-11-09 | $7.45M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $11.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $12.77M 10-Q · filed 2020-08-10 | $9.29M derived: sum of 3 quarters · filed 2021-03-01 | $7.39M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $1.14M 10-Q · filed 2020-05-08 | -$2.34M derived: sum of 2 quarters · filed 2021-03-01 | -$4.24M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2018-12-31 | -$3.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$5.38M derived: sum of 2 quarters · filed 2021-03-01 | $159.00K 10-K · filed 2021-03-01 | |
| 2018-09-30 | -$1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $3.65M 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $5.54M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |